Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Amalgamated Bank

Amalgamated Bank lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 25,856 shares of the biopharmaceutical company's stock after selling 1,191 shares during the period. Amalgamated Bank's holdings in Regeneron Pharmaceuticals were worth $22,709,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of REGN. FMR LLC boosted its position in Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock worth $8,098,661,000 after acquiring an additional 669,517 shares during the period. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 76,169.5% during the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company's stock valued at $519,148,000 after buying an additional 590,314 shares during the period. abrdn plc raised its position in shares of Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company's stock worth $193,136,000 after buying an additional 186,215 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company's stock worth $190,170,000 after acquiring an additional 122,103 shares during the period. Finally, TD Asset Management Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 64.4% in the third quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company's stock valued at $148,353,000 after acquiring an additional 70,628 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 2.1 %

REGN stock traded up $19.39 during midday trading on Friday, reaching $957.00. The company had a trading volume of 547,361 shares, compared to its average volume of 499,907. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $105.04 billion, a P/E ratio of 27.54, a PEG ratio of 2.59 and a beta of 0.17. The company has a 50 day moving average of $944.24 and a two-hundred day moving average of $895.54.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $10.96 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on REGN. Truist Financial reissued a "buy" rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an "underperform" rating in a report on Friday, April 12th. TD Cowen raised their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a "buy" rating in a research note on Wednesday, April 24th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an "outperform" rating and a $1,125.00 price target on the stock. Finally, UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a "buy" rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $977.77.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company's stock, valued at $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Marion Mccourt sold 1,000 shares of the firm's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,095 shares of company stock valued at $9,664,476. 8.83% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.